A096760 Stock Overview
Operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 4/6 |
Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
JW Holdings Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩3,010.00 |
52 Week High | ₩3,905.00 |
52 Week Low | ₩2,650.00 |
Beta | 0.59 |
1 Month Change | 2.91% |
3 Month Change | -13.75% |
1 Year Change | -15.42% |
3 Year Change | -4.06% |
5 Year Change | -46.41% |
Change since IPO | 26.74% |
Recent News & Updates
Cautious Investors Not Rewarding JW Holdings Corporation's (KRX:096760) Performance Completely
Sep 20JW Holdings Corporation's (KRX:096760) Shareholders Might Be Looking For Exit
Jun 14Recent updates
Cautious Investors Not Rewarding JW Holdings Corporation's (KRX:096760) Performance Completely
Sep 20JW Holdings Corporation's (KRX:096760) Shareholders Might Be Looking For Exit
Jun 14JW Holdings' (KRX:096760) Soft Earnings Are Actually Better Than They Appear
Mar 25Shareholders Can Be Confident That JW Holdings' (KRX:096760) Earnings Are High Quality
Apr 01Would Shareholders Who Purchased JW Holdings' (KRX:096760) Stock Three Years Be Happy With The Share price Today?
Mar 15Is JW Holdings (KRX:096760) Using Too Much Debt?
Feb 15What Type Of Shareholders Make Up JW Holdings Corporation's (KRX:096760) Share Registry?
Jan 20Do These 3 Checks Before Buying JW Holdings Corporation (KRX:096760) For Its Upcoming Dividend
Dec 24Read This Before Buying JW Holdings Corporation (KRX:096760) For Its Dividend
Dec 06Shareholder Returns
A096760 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 1.9% | -1.7% | -3.7% |
1Y | -15.4% | 0.1% | -10.4% |
Return vs Industry: A096760 underperformed the KR Pharmaceuticals industry which returned 0.1% over the past year.
Return vs Market: A096760 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
A096760 volatility | |
---|---|
A096760 Average Weekly Movement | 4.4% |
Pharmaceuticals Industry Average Movement | 5.7% |
Market Average Movement | 6.6% |
10% most volatile stocks in KR Market | 12.7% |
10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A096760 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A096760's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1945 | n/a | Kyung-Ha Lee | www.jw-holdings.co.kr |
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair care, beauty care, and other cosmetics products; infant care system, gynecological examining table, sterilizer equipment, diagnostic imaging equipment, operating room equipment, non-PVC film, tube, and empty bag, and health supplements.
JW Holdings Corporation Fundamentals Summary
A096760 fundamental statistics | |
---|---|
Market cap | ₩216.93b |
Earnings (TTM) | ₩68.22b |
Revenue (TTM) | ₩925.73b |
3.2x
P/E Ratio0.2x
P/S RatioIs A096760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A096760 income statement (TTM) | |
---|---|
Revenue | ₩925.73b |
Cost of Revenue | ₩470.89b |
Gross Profit | ₩454.84b |
Other Expenses | ₩386.61b |
Earnings | ₩68.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 946.63 |
Gross Margin | 49.13% |
Net Profit Margin | 7.37% |
Debt/Equity Ratio | 106.4% |
How did A096760 perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield11%
Payout RatioDoes A096760 pay a reliable dividends?
See A096760 dividend history and benchmarksJW Holdings dividend dates | |
---|---|
Ex Dividend Date | Dec 27 2024 |
Dividend Pay Date | Apr 28 2025 |
Days until Ex dividend | 5 days |
Days until Dividend pay date | 127 days |
Does A096760 pay a reliable dividends?
See A096760 dividend history and benchmarksCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 03:51 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
JW Holdings Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jayaprabha Dhavale | Virtua Research Inc. |